2型糖尿病合并骨质疏松症的骨折风险评估和治疗研究进展
Research Progress in Fracture Risk Assessment and Treatment for T2DM Complicated with Osteoporosis
DOI: 10.12677/acm.2025.1582310, PDF,   
作者: 刘诗怡, 李桂琼*：重庆医科大学第二附属医院全科医学科，重庆
关键词: 2型糖尿病；骨质疏松症；骨折；风险评估；药物治疗；Type 2 Diabetes Mellitus； Osteoporosis； Fracture； Risk Assessment； Drug Therapy
摘要: 2型糖尿病(type 2 diabetes mellitus, T2DM)患者的骨密度通常保持正常或增加，但他们的骨折风险却比非糖尿病患者更高。这使得T2DM患者成为一个高度易感的群体，需要特别关注骨骼健康管理。然而，传统的骨折风险评估方法，包括双能X线吸收法和骨折风险评估工具低估了T2DM患者的骨折风险。随着骨折风险评估方法的发展和新型降糖药物治疗地位的显著提高，尽管有证据表明T2DM合并骨质疏松症(osteoporosis, OP)与骨折风险有关，但目前缺乏专门针对T2DM患者的随机对照试验来确定最佳的骨折风险评估和治疗方法。因此，本文旨在对T2DM合并OP患者骨折风险评估、新型降糖药物及抗骨质疏松药物治疗的研究现状作一综述，以提供新的理论依据。
Abstract: The bone mineral density of people with type 2 diabetes mellitus (T2DM) usually remains normal or increases, but their risk of fractures is higher than those without diabetes. This makes people with T2DM a highly susceptible group that requires particular attention to skeletal health management. However, traditional methods for assessing fracture risk, including dual-energy X-ray absorptiometry and fracture risk assessment tools, underestimate the fracture risk in people with T2DM. As fracture risk assessment methods evolve and novel hypoglycemic treatments gain prominence, despite evidence linking T2DM and osteoporosis to higher fracture risk, there is a lack of randomized controlled trials for people with T2DM to identify optimal fracture risk assessment and treatment strategies. Therefore, the purpose of this paper is to review the current research on fracture risk assessment, novel hypoglycemic drugs and, anti-osteoporosis drug treatments in T2DM people with OP, in order to provide a new theoretical basis.
文章引用：刘诗怡, 李桂琼. 2型糖尿病合并骨质疏松症的骨折风险评估和治疗研究进展[J]. 临床医学进展, 2025, 15(8): 869-879. https://doi.org/10.12677/acm.2025.1582310

参考文献

[1] Xu, Y., Lu, J., Li, M., Wang, T., Wang, K., Cao, Q., et al. (2024) Diabetes in China Part 1: Epidemiology and Risk Factors. The Lancet Public Health, 9, e1089-e1097. [Google Scholar] [CrossRef] [PubMed]
[2] Tebé, C., Martínez-Laguna, D., Carbonell-Abella, C., Reyes, C., Moreno, V., Diez-Perez, A., et al. (2019) The Association between Type 2 Diabetes Mellitus, Hip Fracture, and Post-Hip Fracture Mortality: A Multi-State Cohort Analysis. Osteoporosis International, 30, 2407-2415. [Google Scholar] [CrossRef] [PubMed]
[3] Koromani, F., Oei, L., Shevroja, E., Trajanoska, K., Schoufour, J., Muka, T., et al. (2019) Vertebral Fractures in Individuals with Type 2 Diabetes: More than Skeletal Complications Alone. Diabetes Care, 43, 137-144. [Google Scholar] [CrossRef] [PubMed]
[4] Dahl, J., Gulseth, H.L., Forsén, L., Hoff, M., Forsmo, S., Åsvold, B.O., et al. (2021) Risk of Hip and Forearm Fracture in Subjects with Type 2 Diabetes Mellitus and Latent Autoimmune Diabetes of Adults. the HUNT Study, Norway. Bone, 153, Article 116110. [Google Scholar] [CrossRef] [PubMed]
[5] Geusens, P., van den Bergh, J., Roux, C., Chapurlat, R., Center, J., Bliuc, D., et al. (2024) The Fracture Phenotypes in Women and Men of 50 Years and Older with a Recent Clinical Fracture. Current Osteoporosis Reports, 22, 611-620. [Google Scholar] [CrossRef] [PubMed]
[6] Khosla, S., Samakkarnthai, P., Monroe, D.G. and Farr, J.N. (2021) Update on the Pathogenesis and Treatment of Skeletal Fragility in Type 2 Diabetes Mellitus. Nature Reviews Endocrinology, 17, 685-697. [Google Scholar] [CrossRef] [PubMed]
[7] Zoulakis, M., Johansson, L., Litsne, H., Axelsson, K. and Lorentzon, M. (2024) Type 2 Diabetes and Fracture Risk in Older Women. JAMA Network Open, 7, e2425106. [Google Scholar] [CrossRef] [PubMed]
[8] Walker, M.D. and Shane, E. (2023) Postmenopausal Osteoporosis. New England Journal of Medicine, 389, 1979-1991. [Google Scholar] [CrossRef] [PubMed]
[9] 刘建民, 朱大龙, 母义明, 等. 糖尿病患者骨折风险管理中国专家共识[J]. 中华骨质疏松和骨矿盐疾病杂志, 2019, 12(4): 319-335.
[10] Leanza, G., Cannata, F., Faraj, M., Pedone, C., Viola, V., Tramontana, F., et al. (2024) Bone Canonical Wnt Signaling Is Downregulated in Type 2 Diabetes and Associates with Higher Advanced Glycation End-Products (AGEs) Content and Reduced Bone Strength. eLife, 12, RP90437.
[11] Napoli, N., Chandran, M., Pierroz, D.D., Abrahamsen, B., Schwartz, A.V. and Ferrari, S.L. (2016) Mechanisms of Diabetes Mellitus-Induced Bone Fragility. Nature Reviews Endocrinology, 13, 208-219. [Google Scholar] [CrossRef] [PubMed]
[12] Sangondimath, G., Sen, R.K. and T., F.R. (2023) DEXA and Imaging in Osteoporosis. Indian Journal of Orthopaedics, 57, 82-93. [Google Scholar] [CrossRef] [PubMed]
[13] Starup-Linde, J. and Vestergaard, P. (2016) Biochemical Bone Turnover Markers in Diabetes Mellitus—A Systematic Review. Bone, 82, 69-78. [Google Scholar] [CrossRef] [PubMed]
[14] Napoli, N., Conte, C., Eastell, R., Ewing, S.K., Bauer, D.C., Strotmeyer, E.S., et al. (2020) Bone Turnover Markers Do Not Predict Fracture Risk in Type 2 Diabetes. Journal of Bone and Mineral Research, 35, 2363-2371. [Google Scholar] [CrossRef] [PubMed]
[15] 张翠平, 陈琳, 徐碧林, 等. 骨小梁评分在2型糖尿病患者中评价骨质量的应用[J]. 中国骨质疏松杂志, 2020, 26(7): 1028-1033.
[16] Leslie, W.D., Johansson, H., McCloskey, E.V., Harvey, N.C., Kanis, J.A. and Hans, D. (2018) Comparison of Methods for Improving Fracture Risk Assessment in Diabetes: The Manitoba BMD Registry. Journal of Bone and Mineral Research, 33, 1923-1930. [Google Scholar] [CrossRef] [PubMed]
[17] Silva, B.C., Boutroy, S., Zhang, C., McMahon, D.J., Zhou, B., Wang, J., et al. (2013) Trabecular Bone Score (TBS)—A Novel Method to Evaluate Bone Microarchitectural Texture in Patients with Primary Hyperparathyroidism. The Journal of Clinical Endocrinology & Metabolism, 98, 1963-1970. [Google Scholar] [CrossRef] [PubMed]
[18] Lin, Y.-C., Wu, J., Kuo, S.-F., Cheung, Y.-C., Sung, C.-M., Fan, C.-M., et al. (2020) Vertebral Fractures in Type 2 Diabetes Patients: Utility of Trabecular Bone Score and Relationship with Serum Bone Turnover Biomarkers. Journal of Clinical Densitometry, 23, 37-43. [Google Scholar] [CrossRef] [PubMed]
[19] Cheung, W.-H., Hung, V.W.-Y., Cheuk, K.-Y., Chau, W.-W., Tsoi, K.K.-F., Wong, R.M.-Y., et al. (2021) Best Performance Parameters of HR-pQCT to Predict Fragility Fracture: Systematic Review and Meta-Analysis. Journal of Bone and Mineral Research, 36, 2381-2398. [Google Scholar] [CrossRef] [PubMed]
[20] Qiu, H., Yang, H., Yang, Z., Yao, Q., Duan, S., Qin, J., et al. (2022) The Value of Radiomics to Predict Abnormal Bone Mass in Type 2 Diabetes Mellitus Patients Based on CT Imaging for Paravertebral Muscles. Frontiers in Endocrinology, 13, Article 963246. [Google Scholar] [CrossRef] [PubMed]
[21] Chen, W., Mao, M., Fang, J., Xie, Y. and Rui, Y. (2022) Fracture Risk Assessment in Diabetes Mellitus. Frontiers in Endocrinology, 13, Article 961761. [Google Scholar] [CrossRef] [PubMed]
[22] Carballido-Gamio, J. (2022) Imaging Techniques to Study Diabetic Bone Disease. Current Opinion in Endocrinology, Diabetes & Obesity, 29, 350-360. [Google Scholar] [CrossRef] [PubMed]
[23] Krieg, M.A., Barkmann, R., Gonnelli, S., Stewart, A., Bauer, D.C., Del Rio Barquero, L., et al. (2008) Quantitative Ultrasound in the Management of Osteoporosis: The 2007 ISCD Official Positions. Journal of Clinical Densitometry, 11, 163-187. [Google Scholar] [CrossRef] [PubMed]
[24] Gonnelli, S., Al Refaie, A., Baldassini, L., De Vita, M. and Caffarelli, C. (2022) Ultrasound-Based Techniques in Diabetic Bone Disease: State of the Art and Future Perspectives. Indian Journal of Endocrinology and Metabolism, 26, 518-523. [Google Scholar] [CrossRef] [PubMed]
[25] Caffarelli, C., Tomai Pitinca, M.D., Al Refaie, A., Ceccarelli, E. and Gonnelli, S. (2021) Ability of Radiofrequency Echographic Multispectrometry to Identify Osteoporosis Status in Elderly Women with Type 2 Diabetes. Aging Clinical and Experimental Research, 34, 121-127. [Google Scholar] [CrossRef] [PubMed]
[26] Schini, M., Johansson, H., Harvey, N.C., Lorentzon, M., Kanis, J.A. and McCloskey, E.V. (2023) An Overview of the Use of the Fracture Risk Assessment Tool (FRAX) in Osteoporosis. Journal of Endocrinological Investigation, 47, 501-511. [Google Scholar] [CrossRef] [PubMed]
[27] Vandenput, L., Johansson, H., McCloskey, E.V., Liu, E., Åkesson, K.E., Anderson, F.A., et al. (2022) Update of the Fracture Risk Prediction Tool FRAX: A Systematic Review of Potential Cohorts and Analysis Plan. Osteoporosis International, 33, 2103-2136. [Google Scholar] [CrossRef] [PubMed]
[28] Zerikly, R. and Demetriou, E.W. (2024) Use of Fracture Risk Assessment Tool in Clinical Practice and Fracture Risk Assessment Tool Future Directions. Women’s Health, 20, 1-6. [Google Scholar] [CrossRef] [PubMed]
[29] Vilaca, T., Schini, M., Harnan, S., Sutton, A., Poku, E., Allen, I.E., et al. (2020) The Risk of Hip and Non-Vertebral Fractures in Type 1 and Type 2 Diabetes: A Systematic Review and Meta-Analysis Update. Bone, 137, Article 115457. [Google Scholar] [CrossRef] [PubMed]
[30] 董玉洁, 刘冀. 骨质疏松性骨折风险评估工具: FRAX、QFracture、Garvan的应用和比较[J]. 临床医学进展, 2021, 11(1): 143-149.
[31] Agarwal, A., Leslie, W.D., Nguyen, T.V., Morin, S.N., Lix, L.M. and Eisman, J.A. (2022) Performance of the Garvan Fracture Risk Calculator in Individuals with Diabetes: A Registry-Based Cohort Study. Calcified Tissue International, 110, 658-665. [Google Scholar] [CrossRef] [PubMed]
[32] Sheu, A., Greenfield, J.R., White, C.P. and Center, J.R. (2022) Assessment and Treatment of Osteoporosis and Fractures in Type 2 Diabetes. Trends in Endocrinology & Metabolism, 33, 333-344. [Google Scholar] [CrossRef] [PubMed]
[33] Schoeb, M., Avci, T.M., Winter, E.M. and Appelman-Dijkstra, N.M. (2023) Safety Outcomes of Impact Microindentation: A Prospective Observational Study in the Netherlands. JBMR Plus, 7, e10799. [Google Scholar] [CrossRef] [PubMed]
[34] Rufus-Membere, P., Anderson, K.B., Holloway-Kew, K.L., Kotowicz, M.A., Diez-Perez, A. and Pasco, J.A. (2025) Associations between Bone Material Strength Index and FRAX Scores. Journal of Bone and Mineral Metabolism, 43, 230-236. [Google Scholar] [CrossRef] [PubMed]
[35] Samakkarnthai, P., Sfeir, J.G., Atkinson, E.J., Achenbach, S.J., Wennberg, P.W., Dyck, P.J., et al. (2020) Determinants of Bone Material Strength and Cortical Porosity in Patients with Type 2 Diabetes Mellitus. The Journal of Clinical Endocrinology & Metabolism, 105, e3718-e3729. [Google Scholar] [CrossRef] [PubMed]
[36] Lekkala, S., Sacher, S.E., Taylor, E.A., Williams, R.M., Moseley, K.F. and Donnelly, E. (2020) Increased Advanced Glycation Endproducts, Stiffness, and Hardness in Iliac Crest Bone from Postmenopausal Women with Type 2 Diabetes Mellitus on Insulin. Journal of Bone and Mineral Research, 38, 261-277. [Google Scholar] [CrossRef] [PubMed]
[37] van Lenthe, G.H., Mueller, T.L., Wirth, A.J. and Müller, R. (2008) Quantification of Bone Structural Parameters and Mechanical Competence at the Distal Radius. Journal of Orthopaedic Trauma, 22, S66-S72. [Google Scholar] [CrossRef] [PubMed]
[38] 谢雨芯, 周素伊, 梅好, 等. 人工智能辅助机会性CT与双能X线骨密度检测在2型糖尿病和非糖尿病患者骨量评估中的比较研究[J]. 重庆医学, 2024, 53(24): 3700-3705.
[39] Kruse, C., Eiken, P. and Vestergaard, P. (2017) Machine Learning Principles Can Improve Hip Fracture Prediction. Calcified Tissue International, 100, 348-360. [Google Scholar] [CrossRef] [PubMed]
[40] Wu, Y., Chao, J., Bao, M. and Zhang, N. (2023) Predictive Value of Machine Learning on Fracture Risk in Osteoporosis: A Systematic Review and Meta-Analysis. BMJ Open, 13, e071430. [Google Scholar] [CrossRef] [PubMed]
[41] Paschou, S.Α., Dede, A.D., Anagnostis, P.G., Vryonidou, A., Morganstein, D. and Goulis, D.G. (2017) Type 2 Diabetes and Osteoporosis: A Guide to Optimal Management. The Journal of Clinical Endocrinology & Metabolism, 102, 3621-3634. [Google Scholar] [CrossRef] [PubMed]
[42] Tao, Y., E, M., Shi, J. and Zhang, Z. (2021) Sulfonylureas Use and Fractures Risk in Elderly Patients with Type 2 Diabetes Mellitus: A Meta-Analysis Study. Aging Clinical and Experimental Research, 33, 2133-2139. [Google Scholar] [CrossRef] [PubMed]
[43] Ma, T., Tian, X., Zhang, B., Li, M., Wang, Y., Yang, C., et al. (2022) Low-Dose Metformin Targets the Lysosomal AMPK Pathway through PEN2. Nature, 603, 159-165. [Google Scholar] [CrossRef] [PubMed]
[44] Liu, D., Bai, J.-J., Yao, J.-J., Wang, Y.-B., Chen, T., Xing, Q., et al. (2021) Association of Insulin Glargine Treatment with Bone Mineral Density in Patients with Type 2 Diabetes Mellitus. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 14, 1909-1917. [Google Scholar] [CrossRef] [PubMed]
[45] Lee, R.H., Sloane, R., Pieper, C., Lyles, K.W., Adler, R.A., Van Houtven, C., et al. (2019) Glycemic Control and Insulin Treatment Alter Fracture Risk in Older Men with Type 2 Diabetes Mellitus. Journal of Bone and Mineral Research, 34, 2045-2051. [Google Scholar] [CrossRef] [PubMed]
[46] Ye, Y., Zhao, C., Liang, J., Yang, Y., Yu, M. and Qu, X. (2019) Effect of Sodium-Glucose Co-Transporter 2 Inhibitors on Bone Metabolism and Fracture Risk. Frontiers in Pharmacology, 9, Article 1517. [Google Scholar] [CrossRef] [PubMed]
[47] Watts, N.B., Bilezikian, J.P., Usiskin, K., Edwards, R., Desai, M., Law, G., et al. (2016) Effects of Canagliflozin on Fracture Risk in Patients with Type 2 Diabetes Mellitus. The Journal of Clinical Endocrinology & Metabolism, 101, 157-166. [Google Scholar] [CrossRef] [PubMed]
[48] Perkovic, V., Jardine, M.J., Neal, B., Bompoint, S., Heerspink, H.J.L., Charytan, D.M., et al. (2019) Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. New England Journal of Medicine, 380, 2295-2306. [Google Scholar] [CrossRef] [PubMed]
[49] Song, P., Chen, T., Rui, S., Duan, X., Deng, B., Armstrong, D.G., et al. (2022) Canagliflozin Promotes Osteoblastic MC3T3-E1 Differentiation via AMPK/RUNX2 and Improves Bone Microarchitecture in Type 2 Diabetic Mice. Frontiers in Endocrinology, 13, Article 1081039. [Google Scholar] [CrossRef] [PubMed]
[50] Tan, J., Guo, A., Zhang, K., Jiang, Y. and Liu, H. (2024) The Effect of Empagliflozin (Sodium-Glucose Cotransporter-2 Inhibitor) on Osteoporosis and Glycemic Parameters in Patients with Type 2 Diabetes: A Quasi-Experimental Study. BMC Musculoskeletal Disorders, 25, Article No. 793. [Google Scholar] [CrossRef] [PubMed]
[51] Kanis, J.A., Johansson, H., McCloskey, E.V., Liu, E., Åkesson, K.E., Anderson, F.A., et al. (2023) Previous Fracture and Subsequent Fracture Risk: A Meta-Analysis to Update FRAX. Osteoporosis International, 34, 2027-2045. [Google Scholar] [CrossRef] [PubMed]
[52] McGuire, D.K., Marx, N., Mulvagh, S.L., Deanfield, J.E., Inzucchi, S.E., Pop-Busui, R., et al. (2025) Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 Diabetes. New England Journal of Medicine, 392, 2001-2012. [Google Scholar] [CrossRef] [PubMed]
[53] Daniilopoulou, I., Vlachou, E., Lambrou, G.I., Ntikoudi, A., Dokoutsidou, E., Fasoi, G., et al. (2022) The Impact of GLP1 Agonists on Bone Metabolism: A Systematic Review. Medicina, 58, Article 224. [Google Scholar] [CrossRef] [PubMed]
[54] Viggers, R., Rasmussen, N.H.H. and Vestergaard, P. (2023) Effects of Incretin Therapy on Skeletal Health in Type 2 Diabetes—A Systematic Review. JBMR Plus, 7, e10817. [Google Scholar] [CrossRef] [PubMed]
[55] Li, X., Li, Y. and Lei, C. (2024) Effects of Glucagon-Like Peptide-1 Receptor Agonists on Bone Metabolism in Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis. International Journal of Endocrinology, 2024, Article 1785321. [Google Scholar] [CrossRef] [PubMed]
[56] Nasser, M.I., Kvist, A.V., Vestergaard, P., Eastell, R., Burden, A.M. and Frost, M. (2023) Sex and Age Group-Specific Fracture Incidence Rates Trends for Type 1 and 2 Diabetes Mellitus. JBMR Plus, 7, e10836. [Google Scholar] [CrossRef] [PubMed]
[57] 王亚雯, 刘靖芳. DPP-4抑制剂对2型糖尿病患者骨代谢的影响及其分子机制[J]. 中国新药与临床杂志, 2023, 42(11): 695-700.
[58] Pechmann, L.M., Pinheiro, F.I., Andrade, V.F.C. and Moreira, C.A. (2024) The Multiple Actions of Dipeptidyl Peptidase 4 (DPP-4) and Its Pharmacological Inhibition on Bone Metabolism: A Review. Diabetology & Metabolic Syndrome, 16, Article No. 175. [Google Scholar] [CrossRef] [PubMed]
[59] Zhang, Y.-S., Zheng, Y.-D., Yuan, Y., Chen, S.-C. and Xie, B.-C. (2021) Effects of Anti-Diabetic Drugs on Fracture Risk: A Systematic Review and Network Meta-Analysis. Frontiers in Endocrinology, 12, Article 735824. [Google Scholar] [CrossRef] [PubMed]
[60] Eastell, R., Vittinghoff, E., Lui, L.Y., Ewing, S.K., Schwartz, A.V., Bauer, D.C., et al. (2022) Diabetes Mellitus and the Benefit of Antiresorptive Therapy on Fracture Risk. Journal of Bone and Mineral Research, 37, 2121-2131. [Google Scholar] [CrossRef] [PubMed]
[61] Ferrari, S., Eastell, R., Napoli, N., Schwartz, A., Hofbauer, L.C., Chines, A., et al. (2020) Denosumab in Postmenopausal Women with Osteoporosis and Diabetes: Subgroup Analysis of FREEDOM and FREEDOM Extension. Bone, 134, Article 115268. [Google Scholar] [CrossRef] [PubMed]
[62] Mori, H., Okada, Y., Kishikawa, H., Inokuchi, N., Sugimoto, H. and Tanaka, Y. (2013) Effects of Raloxifene on Lipid and Bone Metabolism in Postmenopausal Women with Type 2 Diabetes. Journal of Bone and Mineral Metabolism, 31, 89-95. [Google Scholar] [CrossRef] [PubMed]
[63] Jordt, N., Kjærgaard, K.A., Thomsen, R.W., Borgquist, S. and Cronin-Fenton, D. (2023) Breast Cancer and Incidence of Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis. Breast Cancer Research and Treatment, 202, 11-22. [Google Scholar] [CrossRef] [PubMed]
[64] Dhaliwal, R., Hans, D., Hattersley, G., Mitlak, B., Fitzpatrick, L.A., Wang, Y., et al. (2020) Abaloparatide in Postmenopausal Women with Osteoporosis and Type 2 Diabetes: A Post Hoc Analysis of the ACTIVE Study. JBMR Plus, 4, e10346. [Google Scholar] [CrossRef] [PubMed]
[65] Cosman, F., Crittenden, D.B., Adachi, J.D., Binkley, N., Czerwinski, E., Ferrari, S., et al. (2016) Romosozumab Treatment in Postmenopausal Women with Osteoporosis. New England Journal of Medicine, 375, 1532-1543. [Google Scholar] [CrossRef] [PubMed]
[66] Dominguez, L.J., Veronese, N., Marrone, E., Di Palermo, C., Iommi, C., Ruggirello, R., et al. (2024) Vitamin D and Risk of Incident Type 2 Diabetes in Older Adults: An Updated Systematic Review and Meta-Analysis. Nutrients, 16, Article 1561. [Google Scholar] [CrossRef] [PubMed]
[67] Kawahara, T., Suzuki, G., Mizuno, S., Inazu, T., Kasagi, F., Kawahara, C., et al. (2022) Effect of Active Vitamin D Treatment on Development of Type 2 Diabetes: DPVD Randomised Controlled Trial in Japanese Population. British Medical Journal, 377, e066222. [Google Scholar] [CrossRef] [PubMed]
[68] Ferrari, S.L., Abrahamsen, B., Napoli, N., Akesson, K., Chandran, M., Eastell, R., et al. (2018) Diagnosis and Management of Bone Fragility in Diabetes: An Emerging Challenge. Osteoporosis International, 29, 2585-2596. [Google Scholar] [CrossRef] [PubMed]
[69] Chandran, M., Mitchell, P.J., Amphansap, T., Bhadada, S.K., Chadha, M., Chan, D.-C., et al. (2021) Development of the Asia Pacific Consortium on Osteoporosis (APCO) Framework: Clinical Standards of Care for the Screening, Diagnosis, and Management of Osteoporosis in the Asia-Pacific Region. Osteoporosis International, 32, 1249-1275. [Google Scholar] [CrossRef] [PubMed]

为你推荐